PL3305768T3 - Sól sodowa inhibitora transportera kwasu moczowego i jego forma krystaliczna - Google Patents
Sól sodowa inhibitora transportera kwasu moczowego i jego forma krystalicznaInfo
- Publication number
- PL3305768T3 PL3305768T3 PL16799331T PL16799331T PL3305768T3 PL 3305768 T3 PL3305768 T3 PL 3305768T3 PL 16799331 T PL16799331 T PL 16799331T PL 16799331 T PL16799331 T PL 16799331T PL 3305768 T3 PL3305768 T3 PL 3305768T3
- Authority
- PL
- Poland
- Prior art keywords
- sodium salt
- crystalline form
- uric acid
- acid transporter
- transporter inhibitor
- Prior art date
Links
- 108010078791 Carrier Proteins Proteins 0.000 title 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 159000000000 sodium salts Chemical class 0.000 title 1
- 229940116269 uric acid Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510280720 | 2015-05-27 | ||
| EP16799331.0A EP3305768B1 (en) | 2015-05-27 | 2016-05-26 | Sodium salt of uric acid transporter inhibitor and crystalline form thereof |
| PCT/CN2016/083423 WO2016188444A1 (zh) | 2015-05-27 | 2016-05-26 | 一种尿酸转运蛋白抑制剂的钠盐及其结晶形式 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3305768T3 true PL3305768T3 (pl) | 2020-12-28 |
Family
ID=57393793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16799331T PL3305768T3 (pl) | 2015-05-27 | 2016-05-26 | Sól sodowa inhibitora transportera kwasu moczowego i jego forma krystaliczna |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10196361B2 (pl) |
| EP (1) | EP3305768B1 (pl) |
| JP (1) | JP6738350B2 (pl) |
| KR (1) | KR20180006441A (pl) |
| CN (1) | CN107001276B (pl) |
| AU (1) | AU2016269359B2 (pl) |
| BR (1) | BR112017022505A2 (pl) |
| CA (1) | CA2984961C (pl) |
| CY (1) | CY1123262T1 (pl) |
| DK (1) | DK3305768T3 (pl) |
| ES (1) | ES2811325T3 (pl) |
| HR (1) | HRP20201178T1 (pl) |
| HU (1) | HUE051640T2 (pl) |
| LT (1) | LT3305768T (pl) |
| MX (1) | MX379184B (pl) |
| PL (1) | PL3305768T3 (pl) |
| PT (1) | PT3305768T (pl) |
| RS (1) | RS60749B1 (pl) |
| RU (1) | RU2719484C2 (pl) |
| SI (1) | SI3305768T1 (pl) |
| SM (1) | SMT202000421T1 (pl) |
| WO (1) | WO2016188444A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3305768T3 (pl) * | 2015-05-27 | 2020-12-28 | Jiangsu Hengrui Medicine Co., Ltd. | Sól sodowa inhibitora transportera kwasu moczowego i jego forma krystaliczna |
| CN108201529B (zh) * | 2016-12-16 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法 |
| CN110467571B (zh) * | 2018-05-11 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 一种制备环烷基甲酸类衍生物或其可药用盐的方法 |
| WO2025072489A2 (en) | 2023-09-27 | 2025-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA04250253B1 (ar) * | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| MX362747B (es) * | 2013-05-13 | 2019-02-05 | Shanghai hengrui pharmaceutical co ltd | Derivado de ácido cicloalquilo, método de preparación del mismo, y aplicación farmacéutica del mismo. |
| PL3305768T3 (pl) * | 2015-05-27 | 2020-12-28 | Jiangsu Hengrui Medicine Co., Ltd. | Sól sodowa inhibitora transportera kwasu moczowego i jego forma krystaliczna |
-
2016
- 2016-05-26 PL PL16799331T patent/PL3305768T3/pl unknown
- 2016-05-26 HU HUE16799331A patent/HUE051640T2/hu unknown
- 2016-05-26 JP JP2017555478A patent/JP6738350B2/ja not_active Expired - Fee Related
- 2016-05-26 RU RU2017142996A patent/RU2719484C2/ru active
- 2016-05-26 BR BR112017022505-0A patent/BR112017022505A2/pt not_active Application Discontinuation
- 2016-05-26 HR HRP20201178TT patent/HRP20201178T1/hr unknown
- 2016-05-26 CA CA2984961A patent/CA2984961C/en active Active
- 2016-05-26 PT PT167993310T patent/PT3305768T/pt unknown
- 2016-05-26 LT LTEP16799331.0T patent/LT3305768T/lt unknown
- 2016-05-26 ES ES16799331T patent/ES2811325T3/es active Active
- 2016-05-26 AU AU2016269359A patent/AU2016269359B2/en not_active Ceased
- 2016-05-26 EP EP16799331.0A patent/EP3305768B1/en active Active
- 2016-05-26 KR KR1020177035949A patent/KR20180006441A/ko not_active Ceased
- 2016-05-26 SM SM20200421T patent/SMT202000421T1/it unknown
- 2016-05-26 RS RS20200924A patent/RS60749B1/sr unknown
- 2016-05-26 CN CN201680003846.8A patent/CN107001276B/zh active Active
- 2016-05-26 SI SI201630871T patent/SI3305768T1/sl unknown
- 2016-05-26 DK DK16799331.0T patent/DK3305768T3/da active
- 2016-05-26 US US15/574,328 patent/US10196361B2/en active Active
- 2016-05-26 MX MX2017014319A patent/MX379184B/es unknown
- 2016-05-26 WO PCT/CN2016/083423 patent/WO2016188444A1/zh not_active Ceased
-
2018
- 2018-10-11 US US16/157,696 patent/US10358424B2/en active Active
-
2020
- 2020-08-04 CY CY20201100720T patent/CY1123262T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2811325T3 (es) | 2021-03-11 |
| EP3305768A4 (en) | 2019-02-13 |
| SMT202000421T1 (it) | 2020-09-10 |
| KR20180006441A (ko) | 2018-01-17 |
| PT3305768T (pt) | 2020-08-03 |
| CA2984961A1 (en) | 2016-12-01 |
| EP3305768A1 (en) | 2018-04-11 |
| US20180134663A1 (en) | 2018-05-17 |
| US20190040015A1 (en) | 2019-02-07 |
| CN107001276B (zh) | 2020-03-13 |
| CY1123262T1 (el) | 2021-12-31 |
| HUE051640T2 (hu) | 2021-03-01 |
| LT3305768T (lt) | 2020-08-25 |
| CN107001276A (zh) | 2017-08-01 |
| MX2017014319A (es) | 2018-03-07 |
| BR112017022505A2 (pt) | 2018-07-17 |
| RU2017142996A (ru) | 2019-06-27 |
| JP6738350B2 (ja) | 2020-08-12 |
| JP2018515454A (ja) | 2018-06-14 |
| DK3305768T3 (da) | 2020-08-10 |
| HRP20201178T1 (hr) | 2020-11-13 |
| SI3305768T1 (sl) | 2020-10-30 |
| RS60749B1 (sr) | 2020-10-30 |
| US10196361B2 (en) | 2019-02-05 |
| RU2719484C2 (ru) | 2020-04-17 |
| RU2017142996A3 (pl) | 2019-11-20 |
| AU2016269359B2 (en) | 2020-02-06 |
| EP3305768B1 (en) | 2020-07-01 |
| MX379184B (es) | 2025-03-10 |
| CA2984961C (en) | 2023-08-01 |
| US10358424B2 (en) | 2019-07-23 |
| AU2016269359A1 (en) | 2017-11-23 |
| WO2016188444A1 (zh) | 2016-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI560185B (en) | Acid addition salt of trk inhibitor compound | |
| DK2970123T4 (da) | Krystallinsk dihydrochloridhydratsalt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf | |
| HUE050414T2 (hu) | Eljárás hialuronsav nátriumsója elõállítására és tisztítására | |
| SG11201706917WA (en) | Salts of pi3k inhibitor and processes for their preparation | |
| PT3481819T (pt) | Compostos e a sua utilização para reduzir os níveis de ácido úrico | |
| IL259998A (en) | Polymorphic crystalline forms of obeticholic acid | |
| EP3071554A4 (en) | Crystalline forms of lesinurad and its sodium salt | |
| PL3148661T3 (pl) | Sposób oczyszczania kwasu benzoesowego | |
| EP3247761A4 (en) | Use of hydroxyacid to reduce the localized corrosion potential of low dose hydrate inhibitors | |
| IL256127B (en) | Use of benzimidazole history for nocturnal acid reflux | |
| HUE043194T2 (hu) | PLK-4 inhibitor sója és kristályformái | |
| IL248567A0 (en) | Using compounds known as d-amino acid oxidase inhibitors | |
| PL3632904T3 (pl) | Inhibitory urat1 do pobudzania wydalania kwasu moczowego | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| SI3305768T1 (sl) | Natrijeva sol inhibitorja transporterja sečne kisline in kristalinična oblika le-te | |
| IL253726A0 (en) | Preparations for the treatment of inflammatory diseases related to uric acid | |
| EP3199529A4 (en) | Salt of dicarboxylic acid compound | |
| HUE052088T2 (hu) | Neridronsav vagy sójának alkalmazása osteoarthrosis kezelésére | |
| ZA201901155B (en) | Salt and crystal of diaza-benzofluorane compound | |
| GB201617044D0 (en) | Inhibitor of citrate transporter | |
| FIC20170021I1 (fi) | deoksikoolihapon natriumsuola | |
| GB201517998D0 (en) | Inhibitor of citrate transporter | |
| GB201515692D0 (en) | Inhibitor of citrate transporter |